Research
What Executive Order 14401 says about psychedelic research and ibogaine
2026-09-24 ยท 3 min read
On April 18, 2026, President Donald Trump signed Executive Order 14401, Accelerating Medical Treatments for Serious Mental Illness. It tells several federal agencies to support research, coordinate evidence, and consider routes for eligible psychedelic products and patients. Ibogaine is mentioned, but the order does not reserve $50 million for ibogaine or approve it as a treatment. Read the order.
Where the $50 million goes
Section 3 directs the Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), to allocate at least $50 million from existing funds to support and partner with states that have or are developing programs to advance psychedelic drugs for serious mental illnesses. The order lists federal funding, technical assistance, and data sharing as possible forms of support, subject to applicable law. It does not name ibogaine as the sole recipient, identify individual grants, or report money already spent. The accompanying White House fact sheet describes a match with state investment, but the signed order is the controlling text for what was directed.
What the FDA was told to do
Section 2(a) directs the FDA commissioner to provide Commissioner's National Priority Vouchers to appropriate psychedelic drugs that already have Breakthrough Therapy designation and meet the voucher program's criteria. The section does not name ibogaine, award a voucher to an ibogaine product, or waive the evidence needed for approval. The FDA's description of the voucher pilot says its faster review process keeps the usual statutory and regulatory approval standards. A voucher can change how an eligible application is reviewed; it does not establish that the treatment works or guarantee approval.
Access and rescheduling are conditional
Section 2(b) directs the FDA and Drug Enforcement Administration to facilitate and establish a pathway under the federal Right to Try law for eligible patients to access psychedelic drugs, including ibogaine compounds. It also refers to necessary Schedule I handling authorizations for physicians and researchers. This is a direction to agencies to develop a lawful pathway, not a statement that any patient can obtain ibogaine now.
Section 4 calls for HHS and FDA to work with the Department of Veterans Affairs on trial participation, data sharing, and evidence generation, with privacy and other legal limits. Section 5 directs review of a specific Schedule I product only after successful Phase 3 trials for a serious mental health disorder, so that rescheduling can proceed quickly if appropriate for a product ultimately approved by FDA. It does not reschedule ibogaine or other psychedelics on its own. Section 6 makes implementation subject to applicable law and available appropriations.
What researchers should watch next
The useful milestones are concrete: ARPA-H funding notices and awards that show which state programs receive support; FDA voucher decisions tied to named products; published agency rules or procedures for Right to Try and controlled-substance handling; and product-specific trial results, FDA decisions, and any rescheduling action. The executive order sets directions. Those later records will show what was implemented and whether any particular therapy met the required standards.